Q3 FY2026 · ended Sep 30, 2026 · Revenue $305.10M, -8.4% YoY · Filed Nov 5, 2026
Ingevity Corporation (NGVT) files with the SEC under industry code 2800, Chemicals & Allied Products. In Q3 of fiscal 2026, the quarter ended Sep 30, 2026, it reported revenue of $305.1 million and net income of $49.3 million. Free cash flow was $85.5 million. As of Sep 30, 2026 it held $85.4 million in cash and investments and $189.7 million in total debt.
Revenue
$305.10M
-8.4% vs year-ago quarter
Net income
$49.30M
+13.3% vs year-ago quarter
Operating cash flow
$99.20M
-23.5% vs year-ago quarter
Free cash flow
$85.50M
-27.4% vs year-ago quarter
EPS
$1.41
+19.5% vs year-ago quarter
Dividend per share
None
Shares outstanding
33.78M
-6.1% vs year-ago quarter
Net cash
$-104.30M
Q3 FY2026
Operating margin
52.2%
Q4 FY2024
Company profile
- Industry
- Chemicals & Allied Products (SIC 2800)
- Listed as
- NGVT (NYSE)
- Fiscal year ends
- December 31
- Incorporated in
- DE
- Headquarters
- North Charleston, SC
- SEC filer status
- Large accelerated filer
- SEC CIK
- 1653477
Other Chemicals & Allied Products companies
- Akzo Nobel NV AKZOY
- Solstice Advanced Materials Inc. SOLS
- Balchem Corp BCPC
- Perimeter Solutions, Inc. PRM
- Innospec Inc. IOSP
- Chemours Co CC
- OLIN Corp OLN
- Huntsman CORP HUN
Key figures
Fiscal-year totals from the annual reports; switch to Annual for the full-year view. Balance sheet lines are as of each year end.
| Line | Q3 FY2026 Sep 30, 2026 |
Q2 FY2026 Jun 30, 2026 |
Q1 FY2026 Mar 31, 2026 |
Q4 FY2025 Dec 31, 2025 |
Q3 FY2025 Sep 30, 2025 |
|---|---|---|---|---|---|
| Revenue | $305.1M | $314.1M | $258.0M | $255.1M | $333.1M |
| Net income | $49.3M | $35.3M | $59.8M | -$84.6M | $43.5M |
| Diluted EPS | $1.41 | $1.00 | $1.66 | -$2.37 | $1.18 |
| Operating cash flow | $99.2M | -$13.8M | -$2.0M | $97.1M | $129.7M |
| Free cash flow | $85.5M | -$24.1M | -$12.3M | $73.5M | $117.8M |
| Total assets | $1.5B | $1.5B | $1.7B | $1.7B | $1.8B |
| Total liabilities | $1.4B | $1.5B | $1.6B | $1.6B | $1.7B |
| Stockholders' equity | $63.0M | $46.9M | $38.9M | $29.7M | $138.1M |
| Cash and investments | $85.4M | $97.4M | $95.4M | $78.1M | $83.4M |
| Total debt | $189.7M | $180.1M | $162.3M | $180.1M | $133.0M |
Recent SEC filings
| Form | Description | Filed | Period |
|---|---|---|---|
| 10-Q | Quarterly report | Nov 5, 2026 | Sep 30, 2026 |
| 8-K |
Current report
Results of operations
|
Nov 4, 2026 | Nov 4, 2026 |
| 10-Q | Quarterly report | Jul 30, 2026 | Jun 30, 2026 |
| 8-K |
Current report
Results of operations
|
Jul 29, 2026 | Jul 29, 2026 |
| 8-K |
Current report
Officer or director change
|
Jun 24, 2026 | Jun 22, 2026 |
| 10-Q | Quarterly report | May 7, 2026 | Mar 31, 2026 |
All 660 Ingevity Corporation SEC filings
Source: SEC EDGAR filings. This is company-reported data, not investment advice.